HCW Biologics Nets $3.5M Upfront Fee, Launches HCW9302 Phase 1 Trial
HCW Biologics initiated its first-in-human Phase 1 trial of HCW9302 in 30 alopecia areata patients, with safety and dosing readout expected in the first half of 2026. The company received a $3.5 million upfront license fee (net $2.9 million) for HCW11-006 and launched two reagents with published data supporting CAR-T manufacturing efficiency.
1. First-in-Human Trial Initiation
HCW Biologics initiated a multi-center, dose-escalation Phase 1 study of HCW9302 on November 17, 2025, enrolling up to 30 alopecia areata patients. The subcutaneous IL-2 fusion immunotherapeutic is designed to evaluate safety and determine a recommended dose for later-phase trials, with a preliminary data readout slated for H1 2026.
2. $3.5 Million License Deal
On March 16, 2026, the company received a $3.5 million upfront license fee for HCW11-006 from Beijing Trimmune Biotech, netting $2.9 million after taxes and securing a transferable minority equity stake. HCW Biologics may earn further development milestones, double-digit royalties, and can opt back into U.S. rights post-Phase 1, while granting Trimmune a China rights option for HCW9302.
3. Reagent Launch and CAR-T Findings
During 2025, the company launched two proprietary fusion protein molecules, HCW9206 and HCW9201, as commercial reagents to support cell-based immunotherapeutic production. A peer-reviewed publication released March 13, 2026 demonstrated HCW9206’s potential to enhance CAR-T cell manufacturing efficiency and clinical efficacy against cancer and HIV.
4. Q4 and Full Year Financial Results
Revenues plunged to $27,010 in Q4 2025 from $394,804 a year earlier and fell to $54,232 for full-year 2025 versus $2.6 million in 2024, reflecting suspension of the Wugen license agreement. R&D expenses rose 27% year-over-year to $1.3 million in Q4 but declined 15% to $5.4 million for the full year.